Even though the risk was more than doubled, the overall risk of developing wet AMD was very low: only 93 patients taking GLP-1 medications developed wet AMD after three years among over 46,000 patients in the study
In the ongoing quest to achieve not merely longer lives but healthier, more vibrant lives, Retatrutide is emerging as a groundbreaking therapeutic frontier in obesity medicine and longevity care
This machine is designed to be configured with a variety of options such as single or redundant label heads, label coding, and inspection including serialized codes, precise container orientation, integrated feeding systems, and more
eligibility is determined by a licensed clinician
The Results In this study, 3,346 people with obesity, meaning a BMI over 30, but without diabetes started GLP-1 therapy and were compared to 8,343 similar people not using GLP-1 drugs